أعرض في EDS

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates
المؤلفون: C. Wang, Jacques P. Brown, Shuang Huang, Paul D. Miller, Willem F. Lems, Arkadi Chines, A. Singer, Edward Czerwiński, Henry G. Bone, Nicola Pannacciulli, J. Malouf-Sierra
المساهمون: Rheumatology, Amsterdam Movement Sciences - Rehabilitation & Development, Amsterdam Movement Sciences - Restoration and Development, AII - Inflammatory diseases
المصدر: Miller, P D, Pannacciulli, N, Malouf-Sierra, J, Singer, A, Czerwiński, E, Bone, H G, Wang, C, Huang, S, Chines, A, Lems, W & Brown, J P 2020, ' Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates ', Osteoporosis International, vol. 31, no. 1, pp. 181-191 . https://doi.org/10.1007/s00198-019-05233-x
OSTEOPOROSIS INTERNATIONAL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Osteoporosis International, 31(1), 181-191. Springer London
سنة النشر: 2020
مصطلحات موضوعية: musculoskeletal diseases, 0301 basic medicine, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Osteoporosis, Urology, 030209 endocrinology & metabolism, Pooled analysis, 03 medical and health sciences, 0302 clinical medicine, Bone Density, Internal medicine, Bone mineral density, medicine, Bisphosphonate, Humans, Adverse effect, Osteoporosis, Postmenopausal, Femoral neck, Aged, Bone Density Conservation Agents, Diphosphonates, business.industry, Middle Aged, medicine.disease, Postmenopausal women, Rheumatology, Postmenopause, medicine.anatomical_structure, Denosumab, Zoledronic acid, Orthopedic surgery, Female, 030101 anatomy & morphology, business, medicine.drug
الوصف: Summary: Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate. Introduction: We conducted a patient-level pooled analysis of four studies to estimate the efficacy and safety of transitioning to denosumab vs. continuing bisphosphonate treatment in postmenopausal women who previously received oral bisphosphonates. Methods: Patients received 60 mg denosumab once every 6 months or a bisphosphonate (oral alendronate, risedronate, ibandronate, or intravenous zoledronic acid). Endpoints were change from baseline in lumbar spine, total hip, femoral neck, and 1/3 radius BMD at month 12, change from baseline in serum CTX-1 and P1NP, and incidence of adverse events. Results: A total of 2850 randomized patients (1424 bisphosphonate:1426 denosumab) were included in the analysis. Percentage change in BMD was significantly greater (p < 0.001) for denosumab vs. bisphosphonate at each skeletal site; differences in BMD changes ranged from 0.6 to 2.0%. Percentage decrease in serum CTX-1 and P1NP was significantly greater (p < 0.0001) for denosumab vs. bisphosphonate at months 1, 6, and 12; in the denosumab group only, percentage change in serum CTX-1 at month 1 was significantly correlated with percentage change in lumbar spine and total hip BMD at month 12. The incidences of adverse events were similar between treatment groups. Three patients (one bisphosphonate and two denosumab) had atypical femoral fractures, all from the denosumab vs. zoledronic acid study. Conclusion: Postmenopausal women can safely transition from a bisphosphonate to denosumab, which is more effective at improving BMD than continuing with a bisphosphonate. Clinical trials registration: NCT00377819, NCT00919711, NCT00936897, NCT01732770.
اللغة: English
تدمد: 0937-941X
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35744420405ff1b63b3c1f5ce7053b92
https://research.vumc.nl/en/publications/69264bc8-b6ff-4e7a-8ec8-51c206123993
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....35744420405ff1b63b3c1f5ce7053b92
قاعدة البيانات: OpenAIRE
الوصف
تدمد:0937941X